Receive up-to-the-minute news updates on the hottest topics with NewsHub. Install now.

Sobi buys rights to AstraZeneca infant drug for $1.5 billion upfront

November 13, 2018 8:34 AM
116 0

LONDON (Reuters) - AstraZeneca (AZN.L) has taken another step to refocus on priority drugs by selling U.S. rights to a treatment for infant lung infections to Swedish Orphan Biovitrum (SOBIV.ST) for an upfront fee of $1.5 billion.

Around 130 AstraZeneca staff will transfer to Sobi as the Swedish company, widely known as Sobi, takes over marketing of the treatment Synagis in the United States.

Read more

Share in social networks:

Comments - 0